FEED · ENvue Medical, Inc.
$0.36
-0.02 (-6.34%)
At close · Jul 27
Going-concern doubt
— flagged May 18, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company’s ability to continue as a going concern for twelve months from the date of issuance of these interim condensed consolidated financial statements.”View the 10-Q filed May 18, 2026
Market Cap
$2.18M
Shares
6.09M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$2.55M
-0.2%
FY2025
Net Income
-$18.19M
-390.8%
FY2025
Gross Margin
5.99%
-53pp
FY2025
Operating Margin
-896.55%
-756.5pp
FY2025
Diluted EPS
-$26.69
+80.6%
FY2025
Operating Cash Flow
-$9.37M
-272.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.18M | $2.55M | $2.56M | $2.28M | $752K | $1.7M | $623K | $530K | $318K | $239K | $229K | $147K | $203K | |
| $2.45M | $2.4M | $1.05M | $746K | $585K | $925K | $409K | $249K | $158K | $88K | $88K | $49K | $93K | |
| -$271K | $153K | $1.51M | $1.54M | $167K | $770K | $214K | $281K | $160K | $151K | $141K | $98K | $110K | |
| — | 5.99% | 58.95% | 67.32% | 22.21% | 45.43% | 34.35% | 53.02% | 50.31% | 63.18% | 61.57% | 66.67% | 54.19% | |
| $1.7M | $1.76M | $909K | $185K | $283K | $293K | $171K | $514K | $614K | $693K | $584K | $399K | $431K | |
| $2.92M | $2.49M | $720K | $864K | $965K | $1.1M | $993K | $1.1M | $1.21M | $465K | $514K | $377K | $301K | |
| $8.71M | $7.63M | $3.46M | $3.92M | $3.93M | $5.06M | $3.77M | $3.82M | $2.64M | $2.08M | $1.36M | $746K | $589K | |
| — | $855K | — | — | — | — | — | — | — | — | — | — | — | |
| — | $897K | $1000 | $1000 | $1000 | $2000 | $2000 | $4000 | $6000 | — | — | — | — | |
| $24.48M | $23.04M | $5.09M | $4.97M | $5.18M | $6.45M | $4.93M | $5.43M | $4.46M | $3.24M | $2.46M | $1.52M | $1.32M | |
| -$24.75M | -$22.89M | -$3.58M | -$3.44M | -$5.01M | -$5.68M | -$4.72M | -$5.15M | -$4.3M | -$3.09M | -$2.32M | -$1.42M | -$1.21M | |
| — | -896.55% | -140.03% | -150.5% | -666.49% | -335.28% | -757.46% | -971.89% | -1353.14% | -1293.31% | -1011.35% | -968.71% | -596.55% | |
| — | -$21.99M | -$3.58M | -$3.44M | -$5.01M | -$5.68M | -$4.72M | -$5.15M | -$4.3M | — | — | — | — | |
| — | — | $135K | $135K | $347K | — | $147K | $15K | — | — | — | — | — | |
| -$20.42M | -$18.49M | -$3.69M | -$3.68M | -$5.41M | -$14.25M | -$4.31M | -$5.81M | -$4.28M | -$4.93M | -$2.71M | -$2.86M | -$2.6M | |
| -$289K | -$307K | $19K | $29K | $35K | $32K | $15K | -$17K | -$127K | $38K | $117K | $28K | $49K | |
| -$3.82M | -$18.19M | -$3.71M | -$3.71M | -$5.45M | -$14.28M | -$4.33M | -$5.79M | -$4.15M | -$4.97M | -$2.83M | -$2.88M | -$2.65M | |
| — | -712.3% | -144.84% | -162.55% | -724.47% | -842.6% | -694.38% | -1093.21% | -1306.29% | -2077.41% | -1236.24% | -1961.9% | -1303.94% | |
| -$37.52M | -$16.78M | -$3.71M | -$3.71M | -$5.45M | -$14.28M | -$4.26M | -$5.79M | -$4.15M | -$5.81M | -$2.83M | $2.88M | -$2.65M | |
| -$20.13M | -$18.19M | -$3.72M | -$3.76M | -$5.53M | -$14.29M | — | — | — | -$5.81M | -$2.83M | -$2.88M | -$2.65M | |
| USD/shares | — | -$26.69 | -$137.30 | -$233.20 | -$422.40 | -$1,248.50 | — | — | — | — | — | — | — |
| USD/shares | — | -$26.69 | -$137.30 | -$233.20 | -$422.40 | — | — | — | — | — | — | — | — |
| shares | — | 628.53K | 26.99K | 15.91K | 12.91K | 11.44K | 4680.9623 | 3154.2536 | 2931.065 | 2256.3986 | 2081.1227 | 1607.4309 | 70.4586 |
| shares | — | 628.53K | 26.99K | 15.91K | 12.91K | 11.44K | 4680.9623 | 3154.2536 | 2931.065 | 2256.3986 | 2081.1227 | 1607.4309 | 70.4586 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
—
Peer median 0.93×
Peer medians compare against the 35 similar-size Medical Devices companies (of 146 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| NanoVibronix | $1,857,000 | $2,558,000 |
| Envue | $696,000 | — |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| United States | $2,510,000 | $2,450,000 | $2,162,000 | $710,000,000 | $1,627,000 | $467,000 |
| Australia New Zealand | $20,000 | $41,000 | — | — | — | — |
| Other Country | $15,000 | $50,000 | — | — | — | — |
| Europe | $8,000 | $17,000 | $101,000 | $25,000,000 | $18,000 | $147,000 |
| Australia | — | — | $19,000 | $9,000,000 | $6,000 | — |
| Israel | — | — | $1,000 | — | $5,000 | $3,000 |
| India | — | — | — | $3,000,000 | — | $1,000 |
| Other Country | — | — | — | $5,000,000 | $39,000 | $5,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Corporate | $3,194,000 | — |
| NanoVibronix | -$3,244,000 | -$3,582,000 |
| Envue | -$16,451,000 | — |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 |
|---|---|---|
| NanoVibronix | -174.7% | -140% |
| Envue | -2363.6% | — |